english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

"Cutting the Cord: Curtailing Commercial Influence on Healthcare" a conference to be held online, 16-18 June 2021

Organised by the US-based non-profit group PharmedOut, the conference will address commercial influence on healthcare, focussing on how its damaging effects can be mitigated.
1 June 2021

France's Mediator° trial: Servier and the French drug regulatory agency convicted and sentenced

1 June 2021

Rituximab (Mabthera° or other brands) in pemphigus vulgaris: more patients in remission than with other immunosuppressants, lower exposure to corticosteroids, but a risk of cancer

FEATURED REVIEW Rituximab was already authorised in the European Union for various inflammatory diseases and various types of cancer. It has now also been authorised for use in moderate to severe pemphigus vulgaris, as add-on therapy with a tapering course of corticosteroid treatment.
Full review (5 pages) available for download by subscribers.
1 May 2021

In the May issue of Prescrire International: Ciclosporin eye drops (Verkazia°) in severe vernal keratoconjunctivitis

FREE DOWNLOAD Eye drops containing ciclosporin at a concentration of 1 mg/ml (Verkazia°) have been authorised in the European Union for severe vernal keratoconjunctivitis in children from 4 years of age and in adolescents. How do Prescrire's editors rate this drug?
Full text available for free download.
1 May 2021

Orphan drugs: amendment needed

 Editorial  The European orphan drug regulation needs to be amended, to ensure that it better serves patients' interests, and that the public resources invested benefit public health rather than private interests.
1 May 2021

Medical cannabis: an experimental programme in France in 2021

The medical use of Cannabis sativa L., also known as hemp or cannabis, appears to be an option in the treatment of certain types of pain, despite its limited evaluation.
1 May 2021

Baclofen: at moderate doses, an option for some alcohol-dependent patients

In addition to medical support, baclofen, at moderate doses of around 30 mg per day, is an option of limited usefulness.
1 May 2021

Beware of "spin" in clinical trials

"Spin doctors" are not doctors in the medical sense, but rather public relations specialists whose job it is to enhance the image of an entity or individual. "Spin" however, in the sense of massaged facts, exists in medicine, where it obstructs the reliable evaluation of new drugs.
1 May 2021

Larotrectinib (Vitrakvi°) and cancers with an NTRK gene fusion. Grossly inadequate evaluation as of early 2021

FEATURED REVIEW Larotrectinib (Vitrakvi°) is the first drug to have been authorised in the European Union for adults and children with a tumour that harbours an NTRK gene fusion. Is this "targeted therapy" on target? What does its authorisation tell us about the evaluation process?
Full review (5 pages) available for download by subscribers.
1 April 2021

In the April issue of Prescrire International - Hydrochlorothiazide in hypertension: an acceptable first choice

FREE DOWNLOAD In countries where it is available, chlorthalidone is the first-choice thiazide diuretic. In France, where there is no available medicinal product containing chlorthalidone alone, the first-line thiazide diuretic is hydrochlorothiazide. How do these two drugs compare?
Full text available for free download.
1 April 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90